The 'Uncompany' Answer to Building a Company

Life scientists who want to see their ideas pay off but who don't want to get bogged down in bureaucratic drudgery can take heart from a new trend in business organization. Instead of pushing scientists to hire and oversee pricey financial and legal and regulatory experts, a new breed of barebones biopharmaceutical venture capitalists invest early, when the inventors first create their companies, and recruit outside administrators to handle the management. Charles Hadley and Hal Broderson hold

Written byPeg Brickley
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Charles Hadley and Hal Broderson hold executive positions in each of the eight new companies their firm, Rock Hill Ventures in West Conshohocken, Pa., has helped start up; they build the management structure while the scientists work out the product design. "Part of the advantage is you don't have a lot of infrastructure baggage," Broderson says. "When problems happen, you can turn the burn rate on and off like a spigot." The "burn rate," or the amount of cash a company spends during the development stage, is something venture capitalists watch closely. The more business Hadley and Broderson take on, the less money the start-ups have to spend and the further Rock Hill's invested capital stretches. If a buyer offers a nice price for the business early on, no executive egos will get in the way of a deal.

Other venture firms are catching on to the idea, including two ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery